
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ABILIFY ASIMTUFII | Otsuka | N-217006 RX | 2023-04-27 | 2 products, RLD, RS |
| ABILIFY | Otsuka | N-021436 RX | 2002-11-15 | 6 products, RLD |
| ABILIFY MAINTENA KIT | Otsuka | N-202971 RX | 2013-02-28 | 4 products, RLD, RS |
| OPIPZA | Xiamen LP Pharmaceutical | N-216655 RX | 2024-07-22 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| abilify | New Drug Application | 2025-01-29 |
| abilify abilify | New Drug Application | 2013-08-13 |
| abilify abilify discmelt | 2008-08-28 | |
| abilify asimtufii | New Drug Application | 2025-04-04 |
| abilify maintena | New Drug Application | 2025-04-15 |
| abilify maintena kit | New Drug Application | 2013-04-02 |
| abilify mycite | New Drug Application | 2025-01-31 |
| aripiprazole | ANDA | 2025-10-01 |
| aripiprazole oral solution | ANDA | 2016-08-31 |
| aristada | New Drug Application | 2025-01-28 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| schizophrenia | EFO_0000692 | D012559 | F20 |
| schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Aripiprazole, Abilify Maintena Kit, Otsuka Pharm Co Ltd | |||
| 11648347 | 2034-04-06 | DP | |
| 10525057 | 2034-03-08 | U-543, U-1632, U-2723 | |
| 10980803 | 2033-09-24 | U-543, U-1632 | |
| 11154553 | 2033-09-24 | U-814, U-1632, U-3245 | |
| 11344547 | 2033-09-24 | U-814, U-1632, U-3245 | |
| 11400087 | 2033-09-24 | U-814, U-1632, U-3245 | |
| 7807680 | 2024-10-19 | DP | |
| 8030313 | 2024-10-19 | U-543, U-1632 | |
| 8722679 | 2024-10-19 | DP | |
| Aripiprazole, Abilify Mycite Kit, Otsuka | |||
| 9268909 | 2033-10-15 | DP | U-2168 |
| 10517507 | 2032-06-13 | DP | |
| 9320455 | 2031-12-15 | DP | |
| 11229378 | 2031-07-11 | DP | |
| 8547248 | 2030-12-18 | DP | U-2167 |
| 8258962 | 2030-11-25 | DP | |
| 8961412 | 2030-11-17 | DP | |
| 9941931 | 2030-11-04 | DP | |
| 11464423 | 2030-09-15 | DP | |
| 8114021 | 2030-06-21 | DP | |
| 8545402 | 2030-04-27 | DP | |
| 8847766 | 2030-03-29 | DP | U-2167 |
| 9149577 | 2029-12-15 | DP | |
| 8718193 | 2029-12-05 | DP | |
| 9433371 | 2029-09-15 | DP | |
| 8945005 | 2029-08-19 | DP | U-2167 |
| 10441194 | 2029-07-26 | DP | |
| 8956288 | 2029-07-06 | DP | U-2167 |
| 8674825 | 2029-04-09 | DP | U-2170 |
| 9060708 | 2029-03-05 | DP | |
| 9258035 | 2029-03-05 | DP | |
| 9119554 | 2028-12-16 | DP | |
| 9444503 | 2027-11-19 | DP | U-2169 |
| 7978064 | 2026-09-14 | DP | |
| 11476952 | 2026-04-28 | DP | |
| Aripiprazole, Abilify Asimtufii, Otsuka | |||
| 10517951 | 2033-04-23 | DP | U-814, U-3245 |
| 11097007 | 2033-04-23 | DP | U-814, U-3245 |
| 11638757 | 2033-04-23 | DP | U-814, U-3245 |
| 8399469 | 2025-06-29 | DP | |
| 8338427 | 2025-03-15 | DP | U-543, U-1530, U-1633 |
| 8338428 | 2023-08-06 | DP | U-543, U-1530, U-1633 |
| 8759351 | 2023-08-06 | DP | U-1530, U-1633 |
| Aripiprazole, Abilify, Otsuka | |||
| 8759350 | 2027-03-02 | U-1529 | |
| 9125939 | 2026-07-28 | U-1749 | |
| 7115587 | 2024-07-21 | DP | U-764 |
| 7550445 | 2024-07-21 | DP | |
| 8017615 | 2024-06-16 | DP | |
| 9387182 | 2023-12-25 | U-1529 | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 21 | 24 | 52 | 77 | 50 | 217 |
| Psychotic disorders | D011618 | — | F20.81 | 4 | 4 | 15 | 34 | 24 | 79 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 4 | 4 | 27 | 25 | 18 | 77 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 4 | 3 | 19 | 23 | 9 | 57 |
| Depression | D003863 | — | F33.9 | 2 | 5 | 21 | 21 | 7 | 54 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | 14 | 16 | 12 | 44 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 3 | 3 | 6 | 11 | 9 | 31 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 3 | 7 | 5 | 3 | 18 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | 5 | 7 | 13 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | 1 | 7 | 2 | 2 | 12 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | 2 | 1 | — | — | 3 |
| Schizophrenia spectrum and other psychotic disorders | D019967 | — | — | — | — | 2 | — | 1 | 3 |
| Behavioral symptoms | D001526 | — | — | — | — | 2 | — | — | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | 1 | — | — | 2 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Drug therapy | D004358 | — | — | — | 1 | 1 | — | — | 1 |
| Shared paranoid disorder | D012753 | — | F24 | — | 1 | 1 | — | — | 1 |
| Disease progression | D018450 | — | — | — | — | 1 | — | — | 1 |
| Chronic pain | D059350 | — | — | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nervous system diseases | D009422 | — | G00-G99 | 2 | 2 | — | — | 1 | 5 |
| Cocaine-related disorders | D019970 | — | F14 | 2 | 2 | — | — | — | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 1 | — | — | — | 3 |
| Asperger syndrome | D020817 | EFO_0003757 | F84.5 | — | 3 | — | — | — | 3 |
| Trichotillomania | D014256 | — | F63.3 | — | 1 | — | — | 1 | 2 |
| Fragile x syndrome | D005600 | — | Q99.2 | — | 1 | — | — | — | 1 |
| Excoriation disorder | D000096705 | — | — | — | 1 | — | — | — | 1 |
| Impulsive behavior | D007175 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Immunoassay | D007118 | — | — | 1 | — | — | — | — | 1 |
| Central nervous system diseases | D002493 | — | G96.9 | 1 | — | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
| Stuttering | D013342 | — | F80.81 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Microvascular angina | D017566 | — | — | — | — | — | — | 1 | 1 |
| Therapeutic equivalency | D013810 | — | — | — | — | — | — | 1 | 1 |
| Conversion disorder | D003291 | — | F44 | — | — | — | — | 1 | 1 |
| Dissociative disorders | D004213 | — | F44.1 | — | — | — | — | 1 | 1 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 1 | 1 |
| Drug common name | Aripiprazole |
| INN | aripiprazole |
| Description | Aripiprazole is an N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders. It has a role as a H1-receptor antagonist, a serotonergic agonist, a second generation antipsychotic and a drug metabolite. It is a quinolone, a N-arylpiperazine, a N-alkylpiperazine, a dichlorobenzene, an aromatic ether and a delta-lactam. |
| Classification | Small molecule |
| Drug class | antiulcer agents (benzimidazole derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1 |
| PDB | — |
| CAS-ID | 129722-12-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1112 |
| ChEBI ID | 31236 |
| PubChem CID | 60795 |
| DrugBank | DB01238 |
| UNII ID | 82VFR53I78 (ChemIDplus, GSRS) |










